Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxyne Limited (AU:BXN)
ASX:BXN
Holding AU:BXN?
Track your performance easily
BXN Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week Range<AU$0.01 - AU$0.02
Previous CloseAU$0.01
Volume170.80K
Average Volume (3M)4.94M
Market Cap
AU$22.51M
Enterprise ValueAU$20.40M
Total Cash (Recent Filing)AU$2.17M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-1.29
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume1,486,190
30 Day Avg. Volume4,935,624
Standard Deviation0.24
R-Squared0.07
Alpha0.00658
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)10.47
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Bioxyne Limited News
PremiumCompany Announcements
Bioxyne Limited Maps Future in Pharma Industry
PremiumCompany Announcements
Bioxyne Limited Forecasts $28M Revenue from New Contract
PremiumCompany Announcements
Bioxyne Limited Reports Revenue Surge and Widening Losses
PremiumCompany Announcements
Bioxyne Confirms Compliance Amidst Trading Query
PremiumCompany Announcements
Bioxyne Limited Hits Growth Milestone in 2024PremiumCompany Announcements
Bioxyne Partners for Psilocybin Clinical Trials
PremiumCompany Announcements
Bioxyne Forges Alliance for Psilocybin TherapiesPremiumCompany Announcements
Bioxyne Shareholders Show Confidence in GrowthOptions Prices
Currently, No data available
---
Ownership Overview
37.01% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
62.99% Public Companies and
Individual Investors
BXN FAQ
What was Bioxyne Limited’s price range in the past 12 months?
Bioxyne Limited lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Bioxyne Limited’s market cap?
Currently, no data Available
When is Bioxyne Limited’s upcoming earnings report date?
Bioxyne Limited’s upcoming earnings report date is Feb 20, 2025 which is in 153 days.
How were Bioxyne Limited’s earnings last quarter?
Bioxyne Limited released its earnings results on Aug 30, 2024. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Bioxyne Limited overvalued?
According to Wall Street analysts Bioxyne Limited’s price is currently Overvalued.
Does Bioxyne Limited pay dividends?
Bioxyne Limited does not currently pay dividends.
What is Bioxyne Limited’s EPS estimate?
Bioxyne Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioxyne Limited have?
Bioxyne Limited has 2,046,645,400 shares outstanding.
What happened to Bioxyne Limited’s price movement after its last earnings report?
Bioxyne Limited reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bioxyne Limited?
Currently, no hedge funds are holding shares in AU:BXN
---
Bioxyne Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-31.25%
12-Months-Change
Fundamentals
Return on Equity
-136.57%
Trailing 12-Months
Asset Growth
-62.15%
Trailing 12-Months
Company Description
Bioxyne Limited
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. Some of its products include Progastrim and proTract for Atopic Dermatitis. It operates in two segments: wholesale sales and direct sales. The majority of the revenue is generated from Wholesale sales in the United States and Asia.
---
Technical Analysis
---